It seems some of you, I won't mention names (stay quiet John, I'm giving you plausible deniablility if you just don't juimp in front of the bus again) choose not to look at the information even when I spoon feed it to you. I guess it's too many steps to go to the BIOLASE website, and click the [investors] tab to read the lastest news release. There are also a lot of words in said news releases which I fear compounds the lack of research issue.
Here is a piece of the lates news release:
"There are approximately 70,000 veterinarians and nearly 34,000 veterinary clinics in North America. This market segment is expected to increase 35 percent over the next 10 years. There are also more than 100,000 veterinarians and 30,000 veterinary clinics in Europe. Further, according to research from the Freedonia Group, a leading international business research company, consumer spending on domesticated animals in the U.S. alone is forecast to reach $44 billion in 2014."
$44 billion, and growing! Still not getting it? Ok, how big of a piece of a $44 billion pie do you need to make an impact on your wallet? If you're BIOL, your market cap is about 105 million. For discussion sake, would having additional sales of 105 million make a difference to a company whose whole market cap is 105 million? I contend that it would. How much of the $44 B pie is $105 M? It's less than 1/4 of 1%. I'd remind you that this is just one of the multiple markets BIOL is pursuing. I used an arbitrary sales number to illustrate how big just one market is relative to BIOL, a micro-cap stock.
Part of being involved with a growth stock, or speculative stock is accepting that you must try to anticipate what's going to happen and be ahead of the curve. If you want fundamtal numbers to chew on, try a value stock like Colgate, or Pepsi, both of which are good stocks to own ;)
Very well said!!! BIOL is addressing multiple HUGE markets. A little penetration in any of these markets will make a Huge difference to its profitability and increase its capitalization significantly. I like the way Pignatelli has set the table after returning to the helm. AND he continues to set the table in multiple markets. I think BIOL and thus its shareholders will have a very good year this year.
To the point. We agree, and I think people have to hear the message multiple times before it starts to register. I'd be interested, as would other readers, in hearing your perspective more often. As a relative newcomer myself, I suspect you may have a better grasp of the details and history of BIOL than I do. That experience could be invaluable when drilling down.
We just had what I would consider to be three major news releases in less than three weeks. Did they keep any cards close for the conference call on March 6th? What's next; a contract to build an intergalactic moon ray? This thing has to go parabolic at some point when all this news starts translating in to earnings. With so much market share available I don't see y/y growth slowing anytime in the next five, and probably ten years.
I also don't see the stock being significantly affected by an economic downturn, and may even excellerate growth if they have built a better mouse trap that can decrease costs to make procedures more profitable, or affordable. There is an argument for value being added when you factor in the psycological impact of pain. How many more clients can be serviced when the fear of pain is not needed with a painless procedure? How about safety issues for the vet. and animal if he doesn't need to knock out that 1,000 lb Arabian horse to do a painless procedure? Not to mention regulations for animals are less strict than humans, so an animal market might be the "shortest path to ground" for BIOL innovations.